Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis REPLY

被引：0
|
作者：
Papp, Kim A. [1 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：275 / 275
页数：1
相关论文
共 50 条
  • [1] Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Psoriasis
    Wu, Jashin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (03): : 274 - 275
  • [2] Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
    Leonardi, Craig
    Matheson, Robert
    Zachariae, Claus
    Cameron, Gregory
    Li, Linda
    Edson-Heredia, Emily
    Braun, Daniel
    Banerjee, Subhashis
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13): : 1190 - 1199
  • [3] Anti-interleukin-17 treatment of psoriasis
    Jinna, Sphoorthi
    Strober, Bruce
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (04) : 311 - 315
  • [4] To Be 17 Again - Anti-Interleukin-17 Treatment for Psoriasis
    Waisman, Ari
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13): : 1251 - 1252
  • [5] IXEKIZUMAB Anti-IL-17A monoclonal antibody Treatment of psoriasis
    Haddley, K.
    DRUGS OF THE FUTURE, 2015, 40 (07) : 421 - 431
  • [6] A Phase 2 trial of LY2439821, an anti-interleukin-17 monoclonal antibody, given subcutaneously in patients with moderate to severe psoriasis
    Leonardi, C.
    Matheson, R.
    Zachariae, C.
    Cameron, G.
    Li, L.
    Edson, E.
    Braun, D.
    Banerjee, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E18 - E19
  • [7] Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
    Phan, Celine
    Beneton, Nathalie
    Delaunay, Juliette
    Reguiai, Ziad
    Boulard, Claire
    Fougerousse, Anne-Claire
    Cinotti, Elisa
    Romanelli, Marco
    Mery-Bossard, Laure
    Thomas-Beaulieu, Domitille
    Parier, Josiane
    Maccari, Francois
    Perrot, Jean-Luc
    Ruer-Mulard, Mireille
    Bastien, Marie
    Begon, Edouard
    Samimi, Mahtab
    Jacobzone, Caroline
    Quiles-Tsimaratos, Nathalie
    Descamps, Vincent
    Steff, Maud
    Bilan, Paul
    Vermersch-Langlin, Annie
    Kemula, Mathilde
    Amazan, Emmanuelle
    Kupfer-Bessaguet, Ingrid
    Cottencin, Anne-Caroline
    Prignano, Francesca
    Livideanu, Bulai
    Gottlieb, Jeremy
    Beauchet, Alain
    Mahe, Emmanuel
    ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 4
  • [8] Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis
    Papp, K. A.
    Bachelez, H.
    Blauvelt, A.
    Winthrop, K. L.
    Romiti, R.
    Ohtsuki, M.
    Acharya, N.
    Braun, D. K.
    Mallbris, L.
    Zhao, F.
    Xu, W.
    Walls, C. D.
    Strober, B.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (06) : 1537 - 1551
  • [9] Is there room for another anti-interleukin-17 treatment in the crowded psoriasis therapeutic landscape?
    Bergqvist, Christina
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (06) : e76 - e77
  • [10] An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series
    Esme, Pelin
    Botsali, Aysenur
    Akoglu, Gulsen
    Caliskan, Ercan
    SKIN APPENDAGE DISORDERS, 2022, : 342 - 345
12345